Abstract
Comparative data on the clinical efficacy of vaccination in patients with chronic obstructive pulmonary disease (COPD) against pneumococcal infection using 13-valent conjugate vaccine (PCV-13) or 23-valent polysaccharide vaccine (PPV-23) is cited. Background. To evaluate a clinical efficacy (the number of exacerbations, courses of antimicrobial chemother- apy, hospitalizations) of PCV-13 and PPV-23 in patients with chronic obstructive pulmonary disease (COPD). Methods. The study involved 55 patients with COPD. Patients who met inclusion/exclusion criteria were divided in 2 groups: I group of patients received one dose of the vaccine «Prevenar-13» intramuscularly in the left shoul- der (n=32), II group received one dose of the vaccine «Pneumo-23» intramuscularly in the left shoulder (n=23). We estimated the number of exacerbations per year prior to vaccination and during the year after vaccination, the number of courses of antibiotic therapy for a year prior to vaccination and for a year after immunization, the number of hospitalizations for COPD exacerbation during the year prior to vaccination and during the year after immunization. Results. Vaccination of patients with COPD with PCV-13 or PPV-23 was characterized by the same high clinical efficacy, without the expressed benefits in favor of any drug. Conclusion. Vaccination of patients with COPD against pneumococcal infection with PCV-13 or PPV-23 is char- acterized by a high clinical efficacy. High cost of the 13-valent conjugate pneumococcal vaccine vs a polysac- charide vaccine additionally requires a proof of it’s benefit use in patients with COPD. Until such evidences and their wide representation in the scientific literature should be done vaccination of COPD patients with 13-valent conjugate vaccine is still discussable.
Email this article 
Open Access
Access granted
